EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer

Zheng Wang, Yujie Lu, Mengyuan Han, Anqi Li, Miao Ruan, Yiwei Tong, Cuiyan Yang, Xiaotian Zhang, Changbin Zhu, Chaofu Wang, Kunwei Shen, Lei Dong und 1 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07436-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Zheng Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er R…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Carboplatin, Homologous Recombination, Neoadjuvant Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation Project of Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, Innovative Research Team of High-level Local University in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to assess homologous recombination deficiency (HRD) status and its correlation with carboplatin treatment response in early triple-negative breast cancer (TNBC) patients.

Methods

Tumor tissues from 225 consecutive TNBC patients were evaluated with an HRD panel and homologous recombination-related (HRR) gene expression data. HRD positivity was defined as a high HRD score and/or BRCA1/2 pathogenic or likely pathogenic mutation. Clinicopathological factors, neoadjuvant treatment response, and prognosis were analyzed with respect to HRD status in these TNBC patients.

Results

HRD positivity was found in 53.3% of patients and was significantly related to high Ki67 levels ( P = 0.001). In patients who received neoadjuvant chemotherapy, HRD positivity ( P = 0.005) or a high HRD score ( P = 0.003) was significantly associated with a greater pathological complete response (pCR) rate, especially in those treated with carboplatin-containing neoadjuvant regimens (HRD positivity vs. negativity: 50.00% vs. 17.65%, P = 0.040). HRD positivity was associated with favorable distant metastasis-free survival (hazard ratio HR 0.49, 95% confidence interval CI 0.26–0.90, P = 0.022) and overall survival (HR 0.45, 95% CI 0.20–0.99, P = 0.049), irrespective of carboplatin treatment.

Conclusion

TNBC patients with high HRDs had high Ki67 levels and BRCA mutations. HRD-positive TNBC patients treated with carboplatin had a higher pCR rate. Patients with HRD positivity had a better prognosis, irrespective of carboplatin treatment, warranting further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCarboplatinHomologous RecombinationNeoadjuvant TherapyBRCA1 ProteinHumansFemaleMiddle AgedAdultPrognosisAgedBRCA2 ProteinTreatment OutcomeMutationBiomarkers, TumorAntineoplastic AgentsNeoplasm StagingAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

BRCAHomologous recombination deficiencyPathological responsePrognosisTriple-negative breast cancer

Substanzen

CarboplatinBRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBiomarkers, TumorAntineoplastic AgentsBRCA2 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China.
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China.
  • Department of Translational Oncology, Amoy Diagnostics Co., Ltd., Xiamen, 361026, China.
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. wcf11956@rjh.com.cn.
  • Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. kwshen@medmail.com.cn.
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. dl11968@rjh.com.cn.

Förderung

  • Natural Science Foundation Project of Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Innovative Research Team of High-level Local University in Shanghai
  • Shanghai Municipal Education Commission

Zitieren

APA

Wang, Z., Lu, Y., Han, M., Li, A., Ruan, M., Tong, Y., Yang, C., Zhang, X., Zhu, C., Wang, C., Shen, K., Dong, L., & Chen, X. (2024). Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07436-1

Vancouver

Wang Z, Lu Y, Han M, Li A, Ruan M, Tong Y, et al. Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07436-1

BibTeX
@article{Wang2024,
  author = {Wang, Zheng and Lu, Yujie and Han, Mengyuan and Li, Anqi and Ruan, Miao and Tong, Yiwei and Yang, Cuiyan and Zhang, Xiaotian and Zhu, Changbin and Wang, Chaofu and Shen, Kunwei and Dong, Lei and Chen, Xiaosong},
  title = {Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07436-1}
}
Kostenlos starten →